A randomized, double-blind, placebo-controlled ascending dose tolerance study of 619C89 in acute stroke.
D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D007262:Infusions, Intravenous; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D010919:Placebos; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*
D018696:Neuroprotective Agents; D010879:Piperazines; D010919:Placebos; D011743:Pyrimidines; C081980:sipatrigine